Showing results (131-140 of 164) with videos related to
Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumorsIan Krop, Tim Demuth, Tina Guthrie, et al.Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.British Journal of Cancer|May 26, 2018
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trialsTomoya Yokota, Johanna Bendell, Patricia LoRusso, et al.Clinical Trials (London, England)|February 26, 2026
Shaping the future of clinical trials through strategic foresightSharon Lee, Jeff McIntyre, Tracey Robertson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2017
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid TumorsRebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, et al.Toxicological Sciences : an Official Journal of the Society of Toxicology|July 31, 2012
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysisHarvey Wong, Nageshwar R Budha, Kristina West, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced MalignanciesGerald Falchook, Seth Rosen, Patricia LoRusso, et al.Clinical and Translational Science|May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed HepatotoxicityMarije B Overdijk, Kristin Strumane, Ruth Plummer, et al.Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human studyAung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.Cell Reports. Medicine|February 11, 2025
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancersStephane Champiat, Elena Garralda, Vladimir Galvao, et al.Pageof 17